21. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches.
作者: Lorenzo Bianchi.;Giorgio Gandaglia.;Nicola Fossati.;Nazareno Suardi.;Marco Moschini.;Vito Cucchiara.;Marco Bianchi.;Rocco Damiano.;Riccardo Schiavina.;Shahrokh F Shariat.;Francesco Montorsi.;Alberto Briganti.
来源: Urologia. 2017年84卷1期9-19页
The purpose of this study is to review the current literature concerning the indication of pelvic lymph node dissection (PLND), its extent and complications in prostate cancer (PCa) staging, the available tools, and the future perspectives to assess the risk of lymph node invasion (LNI).
22. Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis.
作者: Hao Wu.;Zhenzhai Cai.;Guangrong Lu.;Shuguang Cao.;He Huang.;Yi Jiang.;Weijian Sun.
来源: Tumori. 2017年103卷3期249-254页
To explore the association of c-erbB-2 protein expression with clinicopathological characteristics and prognosis of gastric cancer (GC) after surgery.
23. Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.
作者: Minehiko Inomata.;Ryuji Hayashi.;Kotaro Tokui.;Chihiro Taka.;Seisuke Okazawa.;Kenta Kambara.;Tomomi Ichikawa.;Toru Yamada.;Toshiro Miwa.;Tatsuhiko Kashii.;Shoko Matsui.;Kazuyuki Tobe.
来源: Tumori. 2016年102卷6期606-609页
Amrubicin monotherapy can be an effective treatment option for patients with recurrent small cell lung cancer (SCLC). We conducted this retrospective study to investigate the prognostic factors in patients with recurrent SCLC receiving amrubicin monotherapy.
24. Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder.
作者: Melissa Bersanelli.;Paola Bini.;Enrico Rabaiotti.;Francesco Facchinetti.;Massimo De Filippo.;Beatrice Bortesi.;Sebastiano Buti.;Marcello Tiseo.
来源: Tumori. 2017年103卷1期66-71页
Bone flare reaction as a sign of response to antineoplastic treatment has been redefined, including the onset of new osteoblastic lesions. If misunderstood as skeletal progression, this finding could lead to erroneous therapy discontinuation, changing the disease clinical course. We aim to describe this clinical phenomenon in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene-activating mutations treated with tyrosine kinase inhibitor (TKI).
25. Evaluation of unusual and highly aggressive variant of endometrium cancer: nonendometrioid endometrium carcinoma of the uterus.
作者: Fatma Sert.;Ugur Yılmaz.;Senem Alanyalı.;Arif Aras.;Zeynep Ozsaran.
来源: Tumori. 2017年103卷6期551-556页
To evaluate the survival and treatment outcomes of patients with nonendometrioid endometrium carcinoma after postoperative radiotherapy.
26. Mitogen-activated protein kinase 7 promotes cell proliferation, migration and invasion in SOSP-M human osteosarcoma cell line.
作者: Yan Huang.;Jianhua Yao.;Bing Zhu.;Jianzheng Zhang.;Tiansheng Sun.
来源: Tumori. 2017年103卷5期483-488页
Osteosarcoma (OS) is the most common primary bone tumor and has low cure rates. Our study aimed to evaluate the roles of mitogen-activated protein kinase 7 (MAPK7) in cell proliferation, migration and invasion using the SOSP-M human OS cell line as an in vitro model.
28. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
作者: Chan Y Cheah.;Loretta J Nastoupil.;Peter McLaughlin.;Michelle A Fanale.;Sattva S Neelapu.;Luis E Fayad.;Frederick B Hagemeister.;Nathan H Fowler.
来源: Br J Haematol. 2016年175卷3期531-533页 29. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study.
作者: Camilla Praestegaard.;Susanne K Kjaer.;Michael Andersson.;Marianne Steding-Jensen.;Kirsten Frederiksen.;Lene Mellemkjaer.
来源: Breast Cancer. 2016年23卷6期908-916页
Women with breast cancer are at increased risk of developing skin cancer. Little is known about how tamoxifen affects this risk. We aimed to investigate whether tamoxifen treatment following breast cancer is associated with skin cancer.
30. HER2 mutation status in Japanese HER2-positive breast cancer patients.
作者: Yumi Endo.;Yu Dong.;Naoto Kondo.;Nobuyasu Yoshimoto.;Tomoko Asano.;Yukari Hato.;Mayumi Nishimoto.;Hiroyuki Kato.;Satoru Takahashi.;Ryoichi Nakanishi.;Tatsuya Toyama.
来源: Breast Cancer. 2016年23卷6期902-907页
Human epidermal growth factor receptor 2 (HER2) gene amplification/overexpression is a major therapeutic target in breast cancer, and has been introduced as a predictive biomarker to identify patients who may benefit from therapy with anti-HER2 agents. HER2 somatic mutations have been reported, and these may influence the effect of HER2-targeted drugs.
31. A comparison between digital breast tomosynthesis and full-field digital mammography for the detection of breast cancers.
作者: Woo Jung Choi.;Hak Hee Kim.;Sun Young Lee.;Eun Young Chae.;Hee Jung Shin.;Joo Hee Cha.;Byung Ho Son.;Sei Hyun Ahn.;Young-Wook Choi.
来源: Breast Cancer. 2016年23卷6期886-892页
To evaluate interobserver agreement in full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) in terms of both lesion detection and characterization, and to evaluate the cancer detection rate of standard two-view FFDM compared to various combinations of DBT.
32. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component.
作者: Tomoko Umeda.;Mitsuaki Ishida.;Satoshi Murata.;Tsuyoshi Mori.;Yuki Kawai.;Naoko Itoi.;Kaori Tomida.;Akie Tanaka.;Sachiko Sakai.;Mina Kitamura.;Yoshihiro Kubota.;Ryoji Kushima.;Masaji Tani.
来源: Breast Cancer. 2016年23卷6期869-875页
Invasive micropapillary carcinoma (IMPC) is a distinct histopathological variant of breast carcinoma and frequently develops lymph node metastases. CD44 is a family of transmembrane glycoprotein receptors with multiple variant isoforms (CD44v), which have tissue-specific expression. Previous studies have demonstrated a loss or gain of CD44v and CD44 standard form (CD44s) expression in breast carcinomas. In this study, we analyzed the immunoprofiles of CD44s, CD44v6, and CD44v9 in IMPC and compared them with those in a concurrent invasive carcinoma of no special type (ICNST) component, thus clarifying the significance of CD44 expression in IMPC.
33. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
作者: Takahisa Imamura.;Mutsuko Yamamoto-Ibusuki.;Aiko Sueta.;Tatsuko Kubo.;Atsushi Irie.;Ken Kikuchi.;Toru Kariu.;Hirotaka Iwase.
来源: Breast Cancer. 2016年23卷6期876-885页
Emerging evidence has shown activation of the complement system in cancer tissues and anaphylatoxin C5a release from C5 by cancer cells, suggesting C5a as a component in the cancer microenvironment. We revealed aberrant expression of C5a receptor (C5aR) in various human cancers and C5a-elicited enhancement of C5aR-expressing cancer cell invasion.
34. A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: clinical results with a median follow-up of 26 months.
作者: Takayuki Nose.;Yuki Otani.;Shuuji Asahi.;Iwao Tsukiyama.;Takushi Dokiya.;Toshiaki Saeki.;Ichirou Fukuda.;Hiroshi Sekine.;Naoto Shikama.;Yu Kumazaki.;Takao Takahashi.;Ken Yoshida.;Tadayuki Kotsuma.;Norikazu Masuda.;Eisaku Yoden.;Kazutaka Nakashima.;Taisei Matsumura.;Shino Nakagawa.;Seiji Tachiiri.;Yoshio Moriguchi.;Jun Itami.;Masahiko Oguchi.
来源: Breast Cancer. 2016年23卷6期861-868页
A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy was performed. The first clinical results were reported with a median follow-up of 26 months.
35. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
作者: Hiroko Yamashita.;Akiko Ogiya.;Tadahiko Shien.;Yoshiya Horimoto.;Norikazu Masuda.;Touko Inao.;Tomofumi Osako.;Masato Takahashi.;Yumi Endo.;Mitsuchika Hosoda.;Naoko Ishida.;Rie Horii.;Kieko Yamazaki.;Yuichiro Miyoshi.;Hiroyuki Yasojima.;Nobumoto Tomioka.; .
来源: Breast Cancer. 2016年23卷6期830-843页
Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who received tamoxifen or aromatase inhibitors as adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer.
36. Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution.
作者: Ayaka Shimo.;Koichiro Tsugawa.;Seiko Tsuchiya.;Reiko Yoshie.;Kyoko Tsuchiya.;Tomoko Uejima.;Yasuyuki Kojima.;Arata Shimo.;Ryosuke Hayami.;Toru Nishikawa.;Yukari Yabuki.;Hisanori Kawamoto.;Akihiko Sudo.;Mamoru Fukuda.;Yoshihide Kanemaki.;Ichiro Maeda.
来源: Breast Cancer. 2016年23卷6期851-860页
Nipple-sparing mastectomy (NSM) is an advantageous treatment option, providing a complete cure and good cosmetic results. We tested whether NSM is a surgically and oncologically safe technique.
37. Ultrasound-guided spinal anesthesia for cesarean section in a parturient with spinal metastases.
作者: Mohamed M Tawfik.;Ahmed A Elrefaey.;Mostafa Abdelkhalek.;Amany A Makroum.
来源: J Clin Monit Comput. 2016年30卷6期857-858页
Preprocedural spinal ultrasound appears to decrease the failure rate and complications of neuraxial anesthesia compared to the conventional landmark technique. It is especially beneficial in difficult cases where conventional palpation technique may fail. We recently encountered a parturient with multiple lumbar and cervical spinal metastatic lesions presenting for cesarean section in the third trimester. We used spinal ultrasound to define the appropriate intervertebral space and measure the distance to the ligamentum flavum-dura mater complex. This greatly helped in administering a safe spinal anesthetic and avoiding general anesthesia which might have been hazardous in this patient.
38. Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (<60) and elderly (≥60) patients.
Triple-negative breast cancer (TNBC) has attracted more attention both clinically and experimentally because of its high-risk biological characteristics and lacking of effective treatment method. The tumour characteristics, patterns of recurrence and metastasis, therapy methods and prognosis in younger TNBC patients have been widely formulated, but the relevant data of the elderly people are lacking. We conducted this retrospective study to compare and analyse the above-related characteristics between the younger and elderly patients with TNBC to estimate the relevance for the elderly TNBC patients. A total of 1489 female patients with primary breast cancer were diagnosed and treated at the department of General Surgery, the Chinese PLA General Hospital, China, from January 2004 to December 2008. In the 1489 patients, 302 patients (20.28%) with TNBC histopathologically confirmed were retrospectively analysed. The 302 TNBC patients were divided into two groups: the younger (<60 years) group and the elderly (≥60 years) group. The relevant characteristics of the two groups were compared. There were no statistically significant differences between the two groups in common clinical data of the patients, clinicopathological features of tumour and the features of local recurrences and metastases of tumour, and the 5-year disease-free survival and overall survival were all significantly higher in the elderly group than those in the younger group, although the elderly group patients accepted significantly less radiotherapy and chemotherapy than the younger group patients. The elderly and younger TNBC patients may belong to different subtypes of TNBC and we probably could take a more conservative and cautious attitude in choosing the post-operative adjuvant treatment for the elderly patients with TNBC.
|